Cannabis use and atherosclerotic cardiovascular disease outcomes: A meta-analysis of multinational cohort data.

IF 3.8 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Dm Disease-A-Month Pub Date : 2025-01-11 DOI:10.1016/j.disamonth.2024.101849
Sneha Annie Sebastian, Yash Shah, Camelia Arsene, Geetha Krishnamoorthy
{"title":"Cannabis use and atherosclerotic cardiovascular disease outcomes: A meta-analysis of multinational cohort data.","authors":"Sneha Annie Sebastian, Yash Shah, Camelia Arsene, Geetha Krishnamoorthy","doi":"10.1016/j.disamonth.2024.101849","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While an association between cannabis use and the risk of atherosclerotic cardiovascular diseases (ASCVD) has been reported numerous times, it remains inconclusive as to whether this link is causal in nature. We sought to consolidate data from observational studies to explore the association between ever use of cannabis and ASCVD outcomes, including myocardial infarction, stroke, and a combined measure of any adverse cardiovascular events in comparison to non-users or controls.</p><p><strong>Methods: </strong>We performed a systematic literature search on PubMed, Scopus, ScienceDirect, and Cochrane Library for relevant studies from inception until April 2024. Statistical analyses utilized RevMan 5.4 with a random effects model. The study protocol has been registered with PROSPERO (CRD42024530366).</p><p><strong>Results: </strong>Our analysis incorporated data from 17 studies involving a total of 1,902,481 individuals aged between 18 and 74 years, with a mean follow-up duration of 8.5 years. Upon pooled analysis, no statistically significant association was found between cannabis use and the risk of myocardial infarction compared to non-users, with an RR of 1.25 (95% CI: 0.91-1.71, p = 0.17). Similarly, while the risk of stroke showed no significant association with cannabis use (RR: 1.38, 95% CI: 0.88 to 2.16, p = 0.16), a statistically significant association was observed between ever use of cannabis and the composite of any adverse cardiovascular events (RR: 1.48, 95% CI: 1.16-1.90, p = 0.002).</p><p><strong>Conclusion: </strong>The evident statistical correlations between cannabis use and adverse cardiovascular outcomes underscore its potential as a risk factor for cardiovascular disease, suggesting plausibility for a causal relationship between cannabis use and ASCVD. With rising trends in medical cannabis use and cannabis use disorder across age demographics, heightened risk awareness and informed decision-making regarding cannabis consumption are critical priorities in healthcare and public health initiatives.</p>","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":" ","pages":"101849"},"PeriodicalIF":3.8000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dm Disease-A-Month","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.disamonth.2024.101849","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: While an association between cannabis use and the risk of atherosclerotic cardiovascular diseases (ASCVD) has been reported numerous times, it remains inconclusive as to whether this link is causal in nature. We sought to consolidate data from observational studies to explore the association between ever use of cannabis and ASCVD outcomes, including myocardial infarction, stroke, and a combined measure of any adverse cardiovascular events in comparison to non-users or controls.

Methods: We performed a systematic literature search on PubMed, Scopus, ScienceDirect, and Cochrane Library for relevant studies from inception until April 2024. Statistical analyses utilized RevMan 5.4 with a random effects model. The study protocol has been registered with PROSPERO (CRD42024530366).

Results: Our analysis incorporated data from 17 studies involving a total of 1,902,481 individuals aged between 18 and 74 years, with a mean follow-up duration of 8.5 years. Upon pooled analysis, no statistically significant association was found between cannabis use and the risk of myocardial infarction compared to non-users, with an RR of 1.25 (95% CI: 0.91-1.71, p = 0.17). Similarly, while the risk of stroke showed no significant association with cannabis use (RR: 1.38, 95% CI: 0.88 to 2.16, p = 0.16), a statistically significant association was observed between ever use of cannabis and the composite of any adverse cardiovascular events (RR: 1.48, 95% CI: 1.16-1.90, p = 0.002).

Conclusion: The evident statistical correlations between cannabis use and adverse cardiovascular outcomes underscore its potential as a risk factor for cardiovascular disease, suggesting plausibility for a causal relationship between cannabis use and ASCVD. With rising trends in medical cannabis use and cannabis use disorder across age demographics, heightened risk awareness and informed decision-making regarding cannabis consumption are critical priorities in healthcare and public health initiatives.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
大麻使用和动脉粥样硬化性心血管疾病结局:多国队列数据的荟萃分析
背景:虽然大麻使用与动脉粥样硬化性心血管疾病(ASCVD)风险之间的关联已被多次报道,但这种联系是否具有因果性仍不确定。我们试图整合来自观察性研究的数据,以探索曾经使用大麻与ASCVD结果之间的关系,包括心肌梗死、中风,以及与非使用者或对照组相比任何不良心血管事件的综合测量。方法:系统检索PubMed、Scopus、ScienceDirect和Cochrane图书馆从成立到2024年4月的相关文献。统计分析采用RevMan 5.4,采用随机效应模型。该研究方案已在PROSPERO注册(CRD42024530366)。结果:我们的分析纳入了17项研究的数据,共涉及1,902,481名年龄在18至74岁之间的个体,平均随访时间为8.5年。经汇总分析,与不吸食大麻的人相比,吸食大麻与心肌梗死风险之间无统计学意义的关联,相对危险度为1.25 (95% CI: 0.91-1.71, p = 0.17)。同样,虽然卒中风险与大麻使用无显著关联(RR: 1.38, 95% CI: 0.88至2.16,p = 0.16),但观察到曾经使用大麻与任何不良心血管事件的组合之间存在统计学上显著的关联(RR: 1.48, 95% CI: 1.16至1.90,p = 0.002)。结论:大麻使用与不良心血管结果之间的明显统计相关性强调了其作为心血管疾病危险因素的潜力,表明大麻使用与ASCVD之间存在因果关系。随着各年龄人口中医用大麻使用和大麻使用障碍的上升趋势,提高对大麻消费的风险认识和知情决策是保健和公共卫生举措的关键优先事项。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Dm Disease-A-Month
Dm Disease-A-Month 医学-医学:内科
CiteScore
5.70
自引率
2.50%
发文量
140
审稿时长
>12 weeks
期刊介绍: Designed for primary care physicians, each issue of Disease-a-Month presents an in-depth review of a single topic. In this way, the publication can cover all aspects of the topic - pathophysiology, clinical features of the disease or condition, diagnostic techniques, therapeutic approaches, and prognosis.
期刊最新文献
Atypical Alzheimer's dementia: Addressing the subtypes, epidemiology, atypical presentations, diagnostic biomarkers, and treatment updates. Foreword for Atypical Alzheimer's dementia: Addressing the subtypes, epidemiology, atypical presentations, diagnostic biomarkers, and treatment updates. Foreword: Ecstasy, Molly, MDMA: What health practitioners need to know about this common recreational drug. Foreword: Hallucinogenic amphetamine, cannabis and opioid issues for the primary care practitioner. Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1